Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034186 (pyelonephritis)
 6,144 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Results are presented on the treatment with Inderal of 57 patients with essential hypertension and symptomatic renal hypertension in whom the changes in central and renal haemodynamics were carefully traced. In all the patients with renal hypertension (chronic pyelonephritis, chronic glomerulonephritis) the function of the kidneys was adequate. Inderal when used in a daily dose of 120--160 mg produces a hypotensive effect in patients with stage IB and IIA essential hypertension with unstable symptomatic renal hypertension who have a predominantly hyperkinetic type of the circulation. In such cases the haemodynamic changes manifest themselves in a considerable reduction of the cardiac output at the expense of a slower pulse rate and decreased stroke volume; the total peripheral resistance was moderately elevated. In patients with stage IIB of essential hypertension and in those with persistent and severe symptomatic renal hypertension the hypotensive effect of Inderal given in a daily dose of 480 mg and sometimes even higher was accompanied by a statistically significant decrease in the total peripheral resistance and a moderate reduction of the cardiac output and cardiac index at the expense of a slower pulse rate.
 ...
PMID:[Use of inderal for the treatment of different forms of arterial hypertension]. 119 58

The study of the aggregation capacity of platelets and the coagulation system of the blood by thromboelastography was undertaken in 36 patients with different forms of arterial hypertension. In 11 patients receiving obsidan these tests were repeated every 4-20 days. In patients with hypertension and pyelonephritis the aggregation capacity of platelets was enhanced, and in patients with glomerulonephritis it was not materially changed. All patients showed a shift in the food coagulation system toward moderate hypercoagulation, which did not change much with obsidan. A relationship between the blood pressure (BP) level and the functional properties of platelets was recorded. There was a simultaneous tendency to the decrease of BP and the inhibition of the aggregation capacity of platelets. Obsidan produces antiaggregation effect related to the decreased stability of platelet aggregates.
 ...
PMID:[Effect of adrenergic beta-receptor blockaders on thrombocyte aggregation capacity in arterial hypertension]. 612 51